Abivax SA (ABVX) Stock Forecast & Price Target

Abivax is viewed positively because obefazimod has delivered best-in-disease ulcerative colitis maintenance data, including 39%–40% placebo-adjusted clinical remission and strong endoscopic outcomes, while the additional safety analyses and NMSC review materially reduced prior malignancy concerns. The investment case is also strengthened by a major balance-sheet buffer, with €1,169.5M in pro forma cash at 1H26 and runway guided into 4Q29, alongside the repurchase of outstanding royalty certificates that removed a commercialization overhang. With a UC NDA filing expected in 4Q26 and mid-2027 Crohn’s data, the company is positioned to address a large unmet need in oral IBD therapy and potentially expand into combination regimens.

Abivax is a high-risk, single-asset biotechnology company whose outlook is weighed down by binary clinical and regulatory execution in obefazimod, since any efficacy miss or safety issue could halt development and undermine future commercialization. Although the ABTECT maintenance study showed a largely consistent safety profile, the company still faces meaningful uncertainty from only modestly differentiated discontinuation rates, low but present serious infection risk, and possible non-melanoma skin cancer concerns in a heavily pre-treated UC population. With no diversified operating segment beyond R&D, Abivax remains exposed to sales shortfalls, manufacturing or shipment disruptions, and intense competition from current and future therapies.